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Summary 
Dendritic cells (DC) in nonlymphoid organs can internalize and process foreign antigens before 
migrating to secondary lymphoid tissues to initiate primary immune responses. However, there 
is little information on which stimuli  promote migration of DC from the tissues. Systemic 
administration  of lipopolysaccharide (LPS), which induces in vivo production of cytokines, led 
to  a reduction in  the numbers of major histocompatibility  complex class II-positive (Ia +) 
leukocytes in mouse hearts and kidneys: >95%  of DC were depleted 1-3 d after injection  of 
50 #g LPS. Several lines of evidence indicated that this response was due to migration of DC 
rather than loss of Ia expression or cytotoxic effects. In skin of treated  mice, the number of 
Ia + epidermal Langerhans' cells (LC) was reduced, and "cords" of Ia + leukocytes became evident 
in the dermis. The latter cells expressed little NLDC145 and may have originated from recruited 
or resident DC progenitors. Systemic  administration of recombinant tumor necrosis  factor (rhTNF)-c~ 
resulted in a decrease in numbers of Ia + cells in heart and kidney and of epidermal LC, and 
it also induced dermal cords. Administration of a rh-interleukin (IL)-I resulted in a decrease 
in Ia + cells only in renal meduUa, appeared to activate a subset of epidermal LC, and induced 
dermal cords. Similar  microgram doses of rhlL-2 had no obvious effect.  Treatment with a neutralizing 
anti-TNF antiserum before LPS administration  inhibited the depletion of LC from skin but not 
from heart or kidney. Therefore, TNF-ot and IL-lot may promote DC migration from nonlymphoid 
tissues and may have differential effects on different DC populations,  but it is unclear whether 
they act on DC directly or indirectly (e.g., via other cytokines). 
D 
endritic cells (DC)  1 originate from MHC class II (Ia)- 
negative progenitors in the bone marrow (1). Within 
nonlymphoid tissues, they apparently develop into Ia + cells 
with the capacity to take up and process antigens (2). These 
cells can then migrate into secondary lymphoid tissues and 
mature into lymphoid DC with the specialized costimula- 
tory functions necessary for T cell activation (3). In previous 
studies, it was shown that DC can migrate via the blood 
into the spleen, in addition to their documented migratory 
route via the lymphatics into lymph nodes (4). Other studies 
1 Abbreviations used in this paper: DC, dendritic cell; FBS, fetal bovine 
serum; Ia, MHC class II; I12, Langerhans' cell; PD, PBS lacking calcium 
and magnesium; rh, recombinant human; rm, recombinant murine. 
A preliminary report of this study was presented to the Second Interna- 
tional Symposium on Dendritic Calls in Amsterdam, June 21-25,  1992. 
on the behavior of Langerhans' calls (LC) in skin transplants 
and explants revealed  that the cells  migrated from the epidermis 
into the dermis before leaving the tissue and suggested that 
their migration was promoted by locally produced inflam- 
matory cytokines (5). 
The development and maturation of DC are dependent 
on cytokines such as GM-CSF, TNF-o6 and IL-lot in vitro 
(6), but much remains to be discovered about the mediators 
of DC migration in vivo. The present report focuses on the 
response of interstitial DC from mouse heart and kidney (7) 
and of LC to systemically administered LPS, which has well- 
documented proinflammatory and adjuvant properties,  and 
to systemic recombinant TNF-c~ and IL-lot. 
Materials and Methods 
Experimental Animals 
Male C57BL/6 (H-2 b) and BALB/c (H-2  d) mice were obtained 
from Olac Ltd. (Bicester, UK). C3H/HeN  (H-2  k,  lps  a)  and 
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tories (Bar Harbor, ME). All animals used were between 6 and 
24 wk of age. 
Reagents 
RIO.  Complete culture medium (K10) was RPMI 1640 sup- 
plemented with 10% heat-inactivated fetal bovine serum (FBS) (both 
from Gibco BRL, Paisley, UK), 2 mM r-glutamine (BDH Chem- 
icals, Merck Ltd., Atherstone, UK), 25 #M 2-ME (Bio-Rad Labora- 
tories Ltd., Hemel Hempstead, UK), 45 #g/ml penicillin, 45/~g/ml 
streptomycin, and 90 #g/ml kanamycin (antibiotics from Gibco 
BRL). PD is PBS lacking calcium and magnesium. 
mAbs.  The following rat anti-mouse mAbs were used as tissue 
culture supernatants (TIB and HB refer to American Type Culture 
Collection [Rockville, MD] designations): M1/9,3.4 (TIB122) anti- 
CD45; B21-2 (TIB229) antiqAb'd; 2.4G2 (HB 197) anti-CDw32; 
Ser4 antisialoadhesin  (8); F4/80 (HB198) antimacrophage and DC 
subset; M1/70 (TIB128) anti-CD11b;  GK1.5 (TIB207) anti-CD4; 
53-6.72 (TIBI05) anti-CDS; 2D2C anti-CD44 (9); NLDC145 anti- 
DC subset (10); and 7/4 antineutrophil and activated macrophage 
(11). The hamster mAb N418 (I-IB224) anti-CDllc was generously 
provided by Dr. K. Steinman (The Rockefeller University, New 
York).  Biotinylated mouse  anti-IA  k was  obtained  from  Phar- 
Mingen (San Diego, CA). 
LPS and Recombinant  Cytokines 
LPS.  S-chemotype LPS (b2637; Sigma Chemical Co., Poole, 
UK) extracted by the Westphal phenol method and purified chro- 
matography (<1% protein) was dissolved in pyrogenffree normal 
saline at 200/~g/ml,  filtered,  and stored at  -20~ 
Recombinant Human II.,lot (rhlblo~).  rhlL-l~ was generously 
provided by Dr. P. Lomedico (Hoffmann-La Roche, Inc., Nutley, 
NJ). The LPS content was reported to be <0.4 endotoxin units/mg 
protein, and the specific activity was reported to be 3  x  10  s U/mg 
in the D10 assay. It was  stored at  -70~ 
rhlL-2,  rhlb2 (Cetus Corp., Emeryville, CA) was generously 
provided by Dr. M. Dallman (Imperial College, London, UK). The 
LPS content was  reported to be <0.006  ng/mg protein by the 
limulus test,  and specific activity was reported to be 1.8  x  107 
U/rag. It was  stored at  -70~ 
thTNF-cr,  rhTNF-cr (BASF/Knoll, Ludwigshaven, Germany) 
was generously provided by Dr. IL. Evans (Nuffleld Department 
of Anaesthetics,  John Radcliffe Hospital, Oxford, UK). The LPS 
content was reported to be <0.137 ng/mg protein by the limulus 
test, and specific activity in the L929 cytotoxicity assay was deter- 
mined to be 2.4  x  107 U/mg.  It was  stored at  -70~ 
Polyclonal Anti.TNF and Control Antisera.  A  polyclonal an- 
tiserum,  raised  in  rabbits  against  recombinant murine TNF-c~ 
(rmTNF-cr) and purified by ammonium sulphate precipitation, was 
generously provided by Dr. E. Havell (Trudeau Institute, Saranac 
Lake, NY). It had specificity both for TNF-et and TNF-/3, and 
the TNF-neutralizing capacity was determined to be 2.22  x  104 
neutralizing unit/mg protein (see below). A control rabbit IgG 
fraction was similarly prepared from the serum of a New Zealand 
White rabbit that had been screened for the absence of natural anti- 
TNF activity; the purified IgG had no detectable TNF-neutralizing 
activity (see Results). 
Administration of LPS and Cytokines.  Mice were injected intra- 
venously, intraperitoneally,  or subcutaneously with sublethal doses 
of LPS, recombinant cytokines, polyclonal anti-TNF, or appropriate 
carrier solutions. At various times after injection, the animals were 
killed and cryostat sections of organs and tissues were labeled for 
various  markers by immunocytochemical or immunofluorescent 
techniques. 
TNF and Neutralizing Anti-TNF Activity.  A modification of a 
published in vitro assay (12) was used to quantify TNF cytotoxic 
activity in mouse serum. Briefly, 2  x  104 routine L929B cells in 
100/~1 R10 were seeded into 96-well flat-bottomed microdilution 
plates (Falcon 3072; Becton Dickinson, Oxford, UK) and incubated 
overnight at 37~  in a humidified 5% CO2 atmosphere. Sequen- 
tial twofold dilutions of test samples were prepared in R10 con- 
raining 2 ~g/ml actinomycin D (Calbiochem Corporation, La JoUa, 
CA) and 100/~1 of each dilution was added to replicate wells of 
the L929B-seeded microdilution plates. After 24 h incubation, cyto- 
toxicity was scored microscopically and by crystal violet absorbance. 
The cytotoxicity titer (U/ml) was defined as the highest dilution 
of test sample that caused the destruction of at least 50% of the 
L929B cells. To ensure specificity of the assay, additional aliquots 
of each sample were preincubated for 1 h with an excess of the 
polyclonal anti-TNF antiserum (above) and tested in parallel with 
test samples. 
To assay the neutralizing capacity of the anti-TNF antiserum, 
sequential  twofold dilutions of test samples in K10 containing 2 
/~g/ml actinomycin D were incubated with an rhTNF-~ standard 
(National Institute of Biological Standards,  Potters Bar, UK) at 
10 U/ml for 1 h at 37~  The samples were added to replicate 
wells of L929B-seeded microdilution plates,  and the cytotoxicity 
titer was determined as above. One neutralizing unit was defined 
as the concentration of antiserum required to neutralize 10 U/ml 
of rhTNF-cr  in vitro. 
Tissue Samples 
Cryosections.  Tissue samples were embedded in OCT compound 
(Tissue-Tek|  Miles, Inc., Elkhart, IN), and 7-10-/~m cryosections 
were prepared and stored at  -30~ 
Skin ExFlants.  Ear skin was split into dorsal and ventral por- 
tions, and epidermal and dermal sheets were prepared before (fresh 
skin)  or after culture on R10 for 1-3 d  (skin  explants)  as de- 
scribed (5). 
Immunocytocbemistry of Cryosections.  Samples were fixed in ace- 
tone (BDH Chemicals,  Merck Ltd.) for 10 min, air dried, and re- 
hydrated. Endogenous peroxidase activity was blocked by incubating 
with a solution of 0.3% H202 and 0.1% NaN3 in PD containing 
1% FBS for 10 rain at room temperature. Cryosections were in- 
cubated with saturating concentrations of rat mAb supernatant 
followed by  peroxidase-conjugated  mouse  anti-rat  IgG  (1:50; 
Jackson ImmunoKesearch Laboratories,  Inc., West Grove, PA). To 
label C3H/HeN and C3H/HeJ cryosections for IA  k, biotinylated 
mouse anti-IA  k (Pharmingen) was followed by Extravidin-peroxi- 
dase (1:50; E-2886;  Sigma Chemical Co.). Incubations were for 
45 min at room temperature, and all reagents and washes  (three 
times) between each stage were in PD containing 1% FBS. The 
peroxidase was developed with a solution containing 10 mg 3,Y- 
diaminobenzidine tetrahydrochloride (DAB; Sigma Chemical Co.) 
in 20 ml PD and 160/~1 3%  H20~.  Slides were counterstained 
with hematoxylin (Gil's No. 2; Sigma Chemical Co.) or 1% eosin 
(E-4382;  Sigma Chemical Co.) and mounted with DPX (BDH 
Chemicals,  Merck Ltd.). 
Immunofluorescent Labeling of Epidermal and Dermal Sheets.  For 
single-color labeling,  epidermal and dermal sheets were fixed in 
acetone for 20 rain, air dried, and rehydrated. They were then in- 
cubated with saturating concentrations of rat mAb (TIB229) su- 
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munoResearch Laboratories,  Inc.).  For two-color labeling,  tissue 
sheets were fixed and rehydrated, as above, and incubated sequen- 
tially with saturating concentrations of primary rat mAb, FITC 
mouse anti-rat IgG (1:50; Jackson ImmunoResearch Laboratories, 
Inc.), FITC-conjugated Fc-specific goat anti-mouse IgG (1:50; to 
amplify the FITC signal; Sigma Chemical Co.), normal rat serum 
(1:50; to reduce backgrounds), saturating concentrations ofbiotin- 
TIB122 or biotin-TIB229 (for CD45 § or Ia + cells, respectively), 
and  Texas red  streptavidin  (1:1,000;  Jackson  ImmunoResearch 
Laboratories,  Inc.). 
Incubations were for 90 rain at room temperature (20 min for 
rat serum), and all reagents and washes (three times) between each 
stage were in PD containing 1% FBS. Slides were mounted with 
Aquamount (BDH Chemicals,  Merck Ltd.). 
Analysis of Labeled Cryostat Sections.  The number of DC and 
other leukocytes in hearts and kidney cortex was quantified by di- 
rect counts of cells per unit area on immunoperoxidase-labeled 
cyrostat sections.  The counts were made blinded as to the treat- 
ment received, and between 5 and 15 randomly selected fields were 
counted for each mAb on sections  from each individual animal. 
Results were expressed as the mean (+  SD) cells per field or per 
square  millimeter. 
In the kidney medulla, where the densely packed leukocytes were 
difficult to distinguish from one another, direct counts were un- 
reliable and a morphometric method was used (13). The method 
was also applied to the kidney cortex. Briefly, a grid (or graticule) 
was superimposed on the tissue section and the number of grid 
intersections overlying positively labeled cells was counted. The 
proportion of the area labeled was the ratio of the number of posi- 
tive intersections to the total number of grid intersections. Counts 
were performed by a single observer, blinded as to the treatment 
received, and results were reported as the percent area positive. For 
each of two labeled sections per kidney,  three randomly selected 
fields (at a magnification of 250) were counted. Kidney cortex and 
medulla were analyzed separately. To maintain an SE of <10%, a 
441-point graticule was  used. 
Analysis of  Epidermal Sheets.  The LC population density within 
epidermal sheets was determined by direct counts of labeled cells 
within a defined area of an ocular grid at a magnification of 625. 
Generally, 10 randomly selected fields on sheets from each animal 
were counted, and results were expressed as the mean (_+ SD) cells 
per field or per square millimeter. The distribution of LC within 
the sheets was remarkably uniform, and, hence, relatively small 
changes in cell density could be detected reliably. 
Cardiac Transplantation.  Hearts  from  C57BL/6  (Ia  b)  donors 
were  transplanted  as  fully vascularized  heterotopic grafts  into 
C3H/HeN (Ia  k) recipients as described (5). Recipients  received 50 
/~g LPS s.c. 6 h after transplantation. They were killed after a fur- 
ther 24 h, and their spleens were examined for migratory donor 
DC (14). 
Migratory donor cells within the recipient spleen were identified 
by labeling 7/~m cryosections with mAb specific for donor Ia. The 
cryosections were fixed in acetone (BDH Chemicals,  Merck Ltd.) 
for 10 rain, air dried, rehydrated, and incubated (45 min, room 
temperature) with saturating concentrations of rat mAb (TIB229; 
anti-Ia TM) supernatant followed by FITC-mouse anti-rat IgG (1:50; 
Jackson ImmunoResearch Laboratories, Inc.). To estimate the den- 
sity of  migratory donor cells within the recipient spleens, the number 
of donor Ia + cells in 100-200 fields (at a magnification  of 312) was 
counted, and the density was expressed  as the mean number of 
cells per square  millimeter. 
Statistics.  Statistical  significance  was determined by applying 
the Student's t test, but, when the data was dearly not normally 
distributed, nonparametric statistics (e.g., Mann-Whitney test) were 
applied. 
Results 
LP$ Depletes Ia + Cells from Mouse Heart and Kidney 
LPS was administered to mice intravenously or subcutane- 
ously, and the number of Ia + cells in cryosections of hearts 
and kidneys was quantified. At 48 h  after a single injection 
of 50 or 100/xg LPS, the number of Ia + cells in both tissues 
was profoundly reduced compared to tissues of untreated or 
carrier-injected mice (Fig. 1). This was preceded, at 4 h, by 
a marked increase in the size of interstitial cells in the renal 
medulla and up-regulation of Ia expression (Fig. I e), as noted 
previously for epidermal LC before their migration into dermis 
(6);  this response was  not observed in the renal cortex or 
in hearts. Although not quantified, LPS administration also 
resulted in loss  of Ia + cells from liver. 
Maximal loss of Ia + cells was induced by 50-100 gg LPS, 
intravenously or subcutaneously, but a reduction in numbers 
could be detected in kidney and heart after a single injection 
of 0.2 and 0.5 gg LPS, respectively (Fig. 2 a). Depletion was 
maximal 1-3 d after LPS injection, but a response was seen 
within 12 h  (Fig. 2 c). The number of Ia + cells returned to 
baseline levels between 4  and 8 d  after injection (Fig. 2 c). 
There were no differences in the dose response to LPS or the 
kinetics of Ia + cell depletion in C57BL/6 (Fig. 2, a and c), 
BALB/c (not shown), or LPS-sensitive C3H/HeN mice (Fig. 
2 b). However, Ia + leukocytes were not depleted from hearts 
of LPS-resistant C3H/HeJ mice (Fig. 2 b), confirming that 
the response was due to LPS rather than to possible non-LPS 
contaminants. 
Ia Loss: Modulation versus Migration.  The apparent loss of 
Ia § cells from heart and kidney is unlikely to have been due 
to loss of Ia expression by interstitial DC (data not shown). 
First, Ia expression by isolated heart and kidney DC and LC 
was not diminished during overnight culture in medium con- 
raining LPS at up to 10 #g/ml (as shown by two-color FACS  | 
analysis), and cell viability was not impaired. Second, there 
was no reduction in the number of Ia §  presumptive inter- 
digitating cells in cryosections of spleens or lymph nodes from 
treated animals, nor in the lungs or mesentery. Third, Ia was 
induced on renal tubular epithelium 24-48 h  after LPS ad- 
ministration (Fig. lJ),  seeming to indicate that local condi- 
tions favored Ia induction rather than down-modulation. This 
is consistent with the known effects of inflammatory medi- 
ators, such as IFN-3', which are induced by LPS (15-18). These 
observations  are  consistent  with  the  hypothesis  that  the 
cytokines elicited by administration of LPS promote the migra- 
tion of DC  from mouse heart  and  kidney. 
Ia Loss: Cytotoxicity versus Migration.  Two lines of evidence 
suggest that the apparent loss of Ia + cells is not due to cy- 
totoxicity. First,  exposure to LPS did not result in loss of 
Ia §  cells  from  LPS-resistant  C3H/HeJ  mice.  This  argues 
strongly against  cytotoxicity of LPS but does not  exclude 
2239  Roake  et al. Figure  1.  Depletion  of la + cells  from heart and kidney after systemic  injection of LPS. Immunoperoxidase  labeling of BALB/c heart (a-c) and kidney 
medulla (d-J) cryosections  for Ia: 48 h after injection of LPS-free carrier (a, d); and 4 h (b, e), or 48 h (c, J) after a single s.c. injection of 100/~g 
LPS. Similar results were obtained using 50 #g LPS and in C57BL/6  mice. Note the profound depletion of la + cells from heart and kidney 48 h 
after  LPS administration, which is preceded  by an increase  in size  and up-regulation  of  la by interstitial  cells  in the renal  medulla. The original magnification 
is 250. 
cytotoxicity from the cytokine cascade induced by LPS in LPS- 
sensitive mice. 
The second line of evidence is provided by transplantation 
experiments.  It  is  known  that  Ia +  donor  cells  can  be  de- 
tected in the spleen of recipients of transplanted normal hearts 
(4, 14) and hearts depleted of Ia + cells by LPS (14), the latter 
apparently due to recruitment of Ia-  DC progenitors.  The 
response  to  LPS  was  examined  further  in  LPS-sensitive 
C3H/HeN recipients of allografted C57BL/6 hearts. Migra- 
tory donor Ia §  cells were detected in the spleens of C3H/ 
HeN recipients that had received 50 #g of LPS s.c. 6 h  after 
transplantation.  However, at 30 h  after transplantation,  the 
density of donor cells was not substantially increased by the 
administration of LPS in comparison to controls that did not 
receive LPS (1.57  +  0.37,  n  =  3,  vs 1.26  _+  0.57,  n  =  3, 
cells/mm2;  P  =  0.475).  This  was  not  surprising  because 
transplantation itself is a potent stimulus to DC migration 
(14), and the rate of disappearance of DC from transplanted 
hearts (4) is not very different than that induced by LPS. This 
experiment, however, provides evidence that LPS did not ini- 
tiate a lethal stimulus for DC in vivo or loss of Ia expression 
on interstitial  DC. 
LPS Recruits  Macrophages  and Neutrophils  into  Mouse Heart 
LPS induced a marked increase in the number of CD45 + 
leukocytes in  the heart,  concomitant  with  the loss  of Ia + 
cells (Fig.  2 d). Many of these cells expressed high levels of 
CD11b/CD18  type 3 complement receptors (CR3),  F4/80, 
and CD32 Fc receptors (FcRII) (Fig. 2, c and d). After isola- 
tion as described (7),  the majority of these  Ia-  leukocytes 
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After injection of 50-100/zg LPS, there was a reproduc- 
ible decrease in the number of epidermal LC at 48 h (com- 
pare Fig. 3 b with a; see Table 1). A subset of the epidermal 
LC increased  in size and expressed higher levels of Ia (Fig. 
3  b).  Within the dermis, "cords" of Ia + leukocytes with 
dendritic morphology became evident at 1-3 d, resembling 
in appearance and distribution those described previously (5) 
in skin transplants and explants (compare Fig. 3 f  to e). An 
important difference,  however,  became apparent after two- 
color immunofluorescent labeling for Ia (or CD45; data not 
shown)  and  the  DC-restricted  marker  NLDC145.  After 
organ culture, dermal cords were composed exclusively  of 
NLDC145 + Ia + leukocytes of similar phenotype to the resi- 
dent LC (compare Fig. 4 a to d). However, after LPS adminis- 
tration, NLDC145 was weak or undetectable on most Ia + 
leukocytes forming dermal cords (compare Fig. 4 b to e). One 
explanation for these findings is that systemic LPS induces 
migration of a  subset  of LC from the  epidermis but  re- 
cruits DC progenitors from blood to dermis or promotes their 
development from  a  resident  Ia-  dermal  population  (see 
also  14). 
Figure  2.  Dose  response and kinetics  of the response to LPS in heart 
and kidney.  Data from  immunoperoxidase  labeling  ofcryosections:  (a) heart 
(1~) and renal  cortex (B) of C57BL/6  mice, and (b) hearts of  LPS-sensitive 
C3H/HeN (W) versus  LPS-resistant  C3H/HeJ ([]) mice, labeled  for Ia, 
48 h after a single  i.v. (a) or s.c. (b) injection of the indicated doses of 
LPS (similar  data  were  obtained  in a after  s.c. injections;  not shown); (c-d) 
hearts of C57BL/6 mice, labeled  for (c) Ia (11), F4/80 (~), and 7/4 ([~), 
and (d) CD45 (I), CD11b (CR.3) (m), and CD32 (FcR) (I~) at the indi- 
cated times  after  a single  s.c. injection  of  50/~g LPS. Each  bar (a-d) represents 
the mean +- SD of counts from 5-10 high power fields  from  each of two 
animals; similar  results  were obtained in two experiments.  Note that the 
content of Ia + interstital  cells in C3H hearts was "~10% that of C57BL/6 
or BALB/c  hearts. 
were cytologically identified as macrophages (data not shown). 
There was also a modest increase in cells expressing the 7/4 
marker, which were cytologically confirmed to be neutro- 
phils (data not shown). Similar observations were noted for 
kidneys of treated mice (data not shown).  These findings, 
and the fact  that DC progenitors were also recruited into 
these tissues (14), make it unlikely that the loss of Ia + cells 
was due to cytotoxicity of LPS for leukocyte stem cells. 
Systemic  Administration  of TNF-ot or IL-Iot,  but Not IL-2, 
Mimics Some of the Responses  to LPS 
TNF-ot and IL-lot are elicited after LPS injection, and both 
cytokines have profound effects on various DC populations 
in vitro (1, 2, 6). Mice were therefore treated with each of 
these recombinant cytokines, and cryosections were exam- 
ined by immunocytochemistry 48  h  later (Table  1). 
TNF~.  rhTNF-o~  induced a  marked loss  of Ia + cells 
from heart, renal cortex, and renal medulla (Table  1).  Ia- 
leukocytes of a similar composition (i.e.,  macrophages and 
neutrophils)  to  that  found after LPS  administration were 
recruited into these tissues (not shown). Epidermal LC were 
depleted (Table 1), and dermal cords became evident. Deple- 
tion of interstitial DC and LC was not increased after a two- 
fold increase  in dose of cytokine, indicating that a plateau 
was reached. 
IL-le~.  rhlL-lot induced a marked loss ofla + cells from 
renal medulla but had no detectable effect on renal cortical 
or cardiac DC (Table 1). Leukocytes were recruited into these 
tissues, but the infiltrating cells were primarily neutrophils, 
with few macrophages (not shown). There was no decrease 
in numbers of epidermal LC (Table 1), but up to 5% of the 
cells increased  in size and expressed higher levels of Ia, and 
dermal cords became evident. These effects were not increased 
by a twofold increase in dose of cytokine. 
IL-2.  None of the above effects were detectable after ad- 
ministration of similar microgram doses of rhlL-2 (Table 1). 
We conclude that TNF-ot, and to a lesser extent IL-lot, 
can mimic some of the responses elicited by LPS. However, 
these molecules function in complex cytokine cascades, and 
each cytokine can,  in certain situations, induce production 
of the other. 
To determine whether or not TNF-ot could mediate the 
effects of LPS administration, studies were carried out with 
2241  Roake  et al. Figure 3.  Ia + cells in skin after systemic injection of LPS or organ culture.  Single-color immunofluorescent labeling for Ia: epidermal (a-c) and 
dermal (d-.~ sheets prepared from normal skin (a, d) skin of mice treated 48 h previously with a single injection of 100/~g LPS s.c. (b, e), and skin 
explants cultured for 48 h (c, J~. Origtnal magnifications were 312 (epidermis) and 125 (dermis). The number of epidermal LC was reduced after LPS 
treatment (see Table 1), and a subset increased in size and expressed higher levels of la. Cords of Ia + cells similar to the appearance after organ culture 
developed in the dermis. After injection of LPS-free carrier, the appearance was similar to that of untreated norma|s. 
neutralizing anti-TNF antibodies in vivo (Fig.  5).  We first 
confirmed that LPS (but not saline carrier) induces a serum 
spike of TNF-c~ in  C57BL/6  mice (Fig.  5  a)  and in  the 
C3H/HeN but not C3H/HeJ mice that were used for studies 
above (Fig.  5 b). This spike was completely neutralized by 
a polyclonal rabbit anti-mouse TNF antiserum, but not by 
control rabbit IgG, administered intravenously 1 h before LPS 
subcutaneously (Fig. 5 c); significant neutralizing activity was 
still present in  the serum 48  h  later (not  shown). 
Pretreatment with anti-TNF antiserum followed by LPS 
had no effect on loss of Ia + cardiac DC, but recruitment of 
7/4 + leukocytes was reduced (Fig. 5 d). Similar observations 
were made in kidneys (not shown).  In skin,  pretreatment 
with  the anti-TNF  antiserum prevented the reduction in 
numbers of epidermal LC by LPS treatment (Fig.  5 e), but 
there was no effect on dermal cord formation (not shown). 
The latter suggests that the cells forming these structures 
were either recruited to the tissue or developed from resident 
precursors. 
We conclude that either neutralization of serum TNFqx 
does not reflect events at the tissue level, or mediators dis- 
tinct from, or in addition to, TNF-o~ are involved in the re- 
sponse of interstitial DC  to LPS. 
Discussion 
Our interpretation of the data is that cytokines induced 
by LPS in vivo are responsible for promoting migration of 
DC from nonlymphoid tissues. In previous studies, cells with 
the phenotypic and functional properties of  DC resided within 
2242  LPS, TNF-or and IL-lot Promote  Dendritic Cell Migration from Tissues Figure 4.  Ia + cells in skin after systemic injection of LPS or organ culture: coexpression of NLDC145.  Two-color immunofluorescent labeling for 
la with Texas red (a-c),  vs the same fields (d-J) labeled for NLDC145  with FITC: dermal (a, b, d, and e), and epidermal (c, J) sheets were prepared 
from skin explants cultured for 48 h (a, d), and skin of mice treated 48 h previously with a single injection of 100 #g LPS s.c. (b, c, e, and./). The 
original magnifications were 400 (dermis) and 500 (epidermis). Dermal cords induced by LPS treatment were composed of la + but NLDC145-, or 
weakly positive, leukocytes (CD45 labeling not shown),  whereas these cells expressed both markers in skin explants. In the epidermis after injection 
of LPS, and in normal skin and skin explants (not shown),  all la + cells expressed NLDC145,  suggesting that LPS had not simply modulated expres- 
sion of NLDC145  by the Ia § cells in the dermis. 
the Ia + subset of leukocytes isolated from mouse heart and 
kidney (7). It is difficult to determine whether or not macro- 
phages also expressed In, but at least those recruited  to the 
tissues by systemic LPS were Ia-  cells (Fig.  2 c).  It  there- 
fore seems reasonable to assume that the profound reduction 
in  numbers  of Ia + cells  induced by LPS relates  at  least in 
part to interstitial DC, although this is less clear for responses 
to systemic cytokines. 
There are three possible explanations for the response to 
LPS:  cell migration,  loss of Ia expression,  or cytotoxicity. 
It is unlikely that  the loss of Ia § cells was due to loss of Ia 
or a cytotoxic effect for the following reasons.  First,  when 
DC were isolated and cultured  in  the presence or absence 
of LPS, there were no differences in Ia expression or cell via- 
bility. Second, presumptive interdigitating cells were readily 
detectable in secondary lymphoid tissues of LPS-treated mice, 
and  Ia + presumptive  DC  were present  in  the  lungs.  It  is 
notable that administration of LPS has in fact been suggested 
to increase the numbers of DC in these tissues (19, 20). Third, 
LPS did not  induce loss of Ia + cells in LPS-resistant  mice 
or  loss  of donor  Ia +  cells  in  the  spleen  of LPS-sensitive 
recipients  of heart transplants.  Fourth, LPS recruited DC pro- 
genitors  to heart  and kidney (14),  and perhaps  also to the 
dermis of skin. Despite this, it is difficult to demonstrate migra- 
2243  Roake et al. Table  1.  Depletion of Ia § Interstitial Cells from Heart and Kidney and of LC from Epidermis after Systemic Administration  of LPS, 
Recombinant  TNF-cr,  IL-lcr,  or IL-2 to G57BL/6 Mice 
Analysis 
Control  Test  Control vs test 
Agent  Number*  Median  Range  Number  Median  Range  Percent change*  P 
Heart 
Kidney 
Renal cortex 
Renal medulla 
Skin 
Epidermis 
Cell count  LPS*  4  199  173-240  10  4.8  0.0-7.6  98  $  <0.001 
Cell count  TNF-aS  6  185  178-371  5  102  92-130  45  ~  0.012 
Cell count  IL-lc~ll  6  220  168-328  6  212  105-284  ~  0.487 
Cell count  IL-21  2  202  184-220  2  191  188-194  "-" 
Cell count  LPS  6  230  184-248  6  5.3  2.1-32.0  98  $  <0.001 
Cell count  TNF-c~  6  228  192-285  5  126  112-210  45  ~  0.005 
Morphometry  LPS  2  25.3  25-25.5  8  1.3  0-5  95  ~  0.001 
Morphometry  TNF-c~  2  17.3  13-21.5  4  8  6-9  54  ~  0.029 
Morphometry  IL-lc~  4  9  7-11  6  8  2.5-12  "~"  0.567 
Morphometry  IL-2  2  15.8  14-17.5  2  16  16-16 
Morphometry  LPS  2  46.8  46.5-47  7  1  0-9.5  98  ~  <0.001 
Morphometry  TNF-cr  2  27  22.5-31.5  4  4.3  3-8.5  84  $  0.003 
Morphometry**  IL-lc~  4  17  15.5-17  6  6.8  1.5-11  60 $  0.001 
Morphometry  IL-2  2  41  43-39  2  32.3  32-32.5 
Cell count  LPS  4  523  448-568  4  403  383-419  23  ~  0.006 
Cen count  TNF-~  4  473  509-458  5  406  436-370  14  ~  0.002 
Cell count  IL-I~  6  483  450-548  6  501  397-535  ",~  0.977 
Cell count  IL-2  2  488  486-489  2  502  539-463  ~" 
Cry*sections of heart and kidney, and epidermal sheets, were prepared from C57BL/6  mice 48 h after a single injection of LPS, cytokine (Test), 
or the appropriate carrier solution (Control), and were labeled for expression of Ia. The tissues were then analyzed by direct counting of positively 
labeled cells or by morphometry.  Cell count values represent the mean number of cells per square millimeter of tissue. Morphometry,  used for the 
kidney analysis, produced quite large variations between experiments, because of variations in the intensity of labeling and variability between batches 
of mice, but it reliably detected differences  between treatment  and control groups within individual experiments (compare renal cortex cell counts 
and morphometry after administration of LPS or TNF-~), Treatment with carrier solutions produced no significant  differences  from untreated animals. 
* Number  of animals. 
~ Arrows indicate a decrease (~), increase (t), or no change ("~). 
r The minimum LPS dosage selected was that required to produce maximum effect based upon dose-response studies up to 100/~g (i.e.,  f>50/zg 
for heart; I>25 #g for kidney; 100 #g for epidermis). Similar results were obtained in more than five experiments. 
S TNF-~ produced no significant effect at doses ~2  x  105 U (8/zg).  Combined data presented from two independent experiments after administra- 
tion of 8  ￿  105 or 1.6  ￿  106  U. 
II Dose-response studies (0.1-50/~g)  indicated that the observed effects of IL-lc~ plateaued at ~10/zg. Heart and skin data presented followed ad- 
ministration of 10 #g IL-I~. Kidney data followed administration of 10-50/~g IL-lcc Similar results were obtained in three independent experiments. 
￿82  The IL-2 data are from a single experiment included as a negative control for the administration of human cytokine. 10/zg of IL-2 was administered 
i.p. The sample size precludes meaningful statistical analysis. 
"*  Data from both untreated and carrier-treated controls are included to facilitate the statistical analysis using the Student's t test. 
tion of DC directly in this model. However, in a rat model, 
LPS administration resulted in an increased flux of veiled cells 
in pseudoafferent lymph that apparently derived from the gut 
wall (21). 
We assume that LPS does not act directly on DC, but that, 
as in other experimental models, its effects are mediated via 
cytokines (15-18).  In these studies, rhTNF-ot and rhlL-lc~ 
were used to determine whether these cytokines can promote 
DC migration. Although many cytokines, including IL-la 
and IL-2,  appear to be fully cross-reactive between mouse 
and human,  and mouse TNF appears to be fully active on 
human cells (22), human TNF is active only in some murine 
bioassays (23-25)  and is less toxic than rmTNF-a to mice 
in vivo (23). Two distinct TNF receptors have been identified 
in the mouse: TNF-K2, which may be species specific, and 
TNF-K1,  which is not  (26).  Since TNF-K1  appears to be 
2244  LPS, TNF-o~ and IL-la Promote Dendritic Cell Migration from Tissues Figure  5.  The effects of a neutralizing anti-TNF an- 
tiserum before LPS treatment.  (a-c) Serum TNF levels 
were measured at the indicated times after injection of: 
(a) 25/~g LPS s.c. (open  circles) or saline carrier s.c. (crosses) 
to C57BL/6 mice; (b) 50/~g LPS s.c. to C3H/HeN (open 
circles) or C3H/HeJ (crosses) mice; and (c) 2  x  104 neu- 
tralizing units of anfi-TNF  (crosses)  or an equivalent micro- 
gram dose of control rabbit IgG (o/x,,n  circles) i.v., 1 h be- 
fore a challenge with 25/*g LPS s.c. Each point represents 
the mean of duplicate assays on serum from each of two 
animals; the limit of detection in each L929 assay  is indi- 
cated by the dashed horizontal line. LPS induced a serum 
TNF spike in C57BL/6 (a) and C3H/HeN (b) mice, but 
not C3H/HeJ mice, that was completely neutralized by 
prior administration of an anti-TNF antiserum. The TNF 
spike induced by 100/~g LPS s.c. was also completely  neu- 
tralized by the same dose of antiserum, and significant 
neutralizing activity was still present in serum 48 h later 
(data not shown). (d, e) C57BL/6 mice were treated as 
indicated: anti-TNF or control IgG was administered (as 
in a-c) before a single s.c. injection of 25/zg (d) or 100 
/~g (e) LPS or saline carrier. After 48 h, heart cryosections 
(d) and epidermal sheets (e) were labeled  for Ia (m), CD45 
(m), F4/80 (m), or 7/4 (~A). Each  bar represents the mean 
_+ SD of cell counts from a minimum of five  high power 
fields (Ia: d,  xS00, e, x625; CD45:  x500; F4/80:  x312; 
7/4:  x312) of tissues from each of four animals (the data 
for 7/4 was not normally distributed so error bars are not 
shown). Similar  results were obtained in two experiments. 
In separate  experiments, administration of polyclonal  anti- 
TNF or control IgG alone had no effect on cells in skin epidermis or dermis (data not shown). Neutralization of the serum TNF spike (see a-c) induced 
by LPS had no effect on depletion of Ia  + interstitial cells from heart (d), but did prevent the reduction in numbers of epidermal LC (e; p  =  0.05, 
Mann-Whimey test, pooled data of two experiments, n  =  8); had no effect on recruitment of the macrophages but did reduce neutrophil recruitment 
to heart (d; p  =  0.036, Mann-Whitney test,  pooled data of two experiments, n  =  8); and had no effect on the induction of dermal cords (semi- 
quantitative data not  shown; P  =  0.4, Mann-Whitney test,  pooled data of two experiments, n  =  8). 
the major signal transduction component for TNF responses 
(27), it seems likely that the responses to human and mouse 
TNF-o~ would be qualitatively (if not quantitatively) similar. 
Administration of rhTNF-oe led to a reduction in the num- 
bers  of cardiac  and  renal  Ia +  ceils  and  of epidermal  LC. 
In other studies, intradermal injection of rmTNF-oe into ear 
skin of mice resulted in increased numbers of DC in draining 
lymph nodes  (28)  and  depletion  of epidermal LC by up  to 
25% 30 min after injection (29), providing evidence that TNF 
can promote LC migration from the skin. TNF has also been 
implicated in the migration of LC to lymph nodes in response 
to UV-B irradiation (30), although it has also been reported 
that UV-B irradiation  or intradermal TNF may transiently 
immobilize LC within the epidermis (31). Treatment of mice 
with  anti-TNF  antiserum  before  LPS  administration  was 
sufficient to prevent the depletion of LC from the epidermis 
but not of cardiac or renal DC. Interpretation of these obser- 
vations is difficult because,  even though  TNF  was neutral- 
ized  within  the  serum,  this  might  not  have been  the  case 
within  the interstitial  spaces of heart  and kidney.  In terms 
of other cytokines,  it has been reported that intraperitoneal 
injection  of IFN-c~ or IFN-3 leads to loss of Ia + cells from 
mouse  kidney  and  heart  (32). 
Administration of rhIL-lol led to a decrease in the number 
of Ia §  cells  in  the renal  medulla,  but,  in contrast  to TNF, 
it  did  not  decrease  the  number  of  Ia §  cells  in  the  renal 
cortex or heart,  nor of epidermal LC (Table  1).  The latter 
is consistent with the finding of Enk et al. (33)  that IL-13, 
but  not  IL-lcz, can induce  migration  of epidermal LC.  In 
other  experiments,  systemic or intracutaneous  injection  of 
IL-13 was reported to decrease the density of epidermal LC 
by up to  50%  between  2  and  7  d  after injection  (34),  but 
injection of IL-1 into the central cornea induced centripetal 
migration of peripheral corneal LC to the site of injection (35). 
In summary, the data  in the present  report indicate  that 
systemic LPS,  TNF-cz,  and  IL-lc~ can promote the migra- 
tion  of different  populations  of DC,  either  directly  or in- 
directly (e.g., by inducing other cytokines). However, given 
the pleiotropic and apparently degenerate nature of cytokine 
activity in general,  it  may prove very difficult  to define in- 
dividual cytokines that mediate DC migration or recruitment 
directly. A role for inflammatory mediators in promotion of 
nonlymphoid DC migration may be physiologically and ther- 
apeutically relevant,  but  it  is  not  clear if local exposure  to 
physiologically relevant  concentrations  of LPS during  bac- 
terial infection would induce local DC migration and leuko- 
cyte recruitment.  It is  tempting,  however,  to  suggest  that 
this may be a component of the early host response to bac- 
terial  invasion. 
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